<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630708</url>
  </required_header>
  <id_info>
    <org_study_id>Nanfang200803</org_study_id>
    <nct_id>NCT00630708</nct_id>
  </id_info>
  <brief_title>Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency</brief_title>
  <acronym>SDBRAS</acronym>
  <official_title>Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the present study is to assess the safety of combined treatment of&#xD;
      benazepril (an ACE inhibitor) or losartan (an ARB) in non-diabetic patients with advanced&#xD;
      renal insufficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interruption of the renin-angiotensin systerm (RAS) with an angiotensin-converting enzyme&#xD;
      (ACE) inhibitor or an angiotensin II receptor blocker (ARB) slows the progression of chronic&#xD;
      renal insufficiency in the presence or absence of diabetes. Even for advanced chronic renal&#xD;
      insufficiency (stage 4 CKD), ACE inhibitors and ARBs can still provide renoprotection. Some&#xD;
      clinical studies showed that dual RAS blockage seemed to enhance the antiproteinuric effect&#xD;
      compared with single-agent ACE inhibitor or ARB and then improve renal survival. However, in&#xD;
      the only one randomized controlled trial investigating the renoprotection of combined ACE&#xD;
      inhibitor and ARB for mild or moderate chronic renal insufficiency (the mean creatinine value&#xD;
      is 2.9mg/dl), the incidence of hyperkalemia was increased in combination therapy compared&#xD;
      with monotherapy. Although increase of hyperkalemia was not statistical significant, it&#xD;
      suggested that combination treatment of ACEI and ARB might increase the incidence of&#xD;
      hyperkalemia in patients with advanced renal insufficiency. However, it is still undetermined&#xD;
      whether combination treatment of ACE inhibitor and ARB is safe as an ACE inhibitor or ARB&#xD;
      monotherapy in advanced non-diabetic chronic renal insufficiency (stage 4 CKD). The primary&#xD;
      aim of the present study is to assess the safety of combined treatment of benazepril (an ACE&#xD;
      inhibitor) or losartan (an ARB) in non-diabetic patients with advanced renal insufficiency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Significant differences observed between groups.&#xD;
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with increase in serum potassium ≥6.0 mmol/L.</measure>
    <time_frame>Every 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with serum creatinine increase &gt;30%</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with drug-related cough</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with hopotension (systolic blood pressure &lt;110 mmHg despite withdrawal of all additional antihypertensive medication)</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with non-fatal cardiovascular events</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">309</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benazepril group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benazepril+Losartan group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benazepril</intervention_name>
    <description>20 mg per day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lotensin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>100 mg per day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benazepril+Losartan</intervention_name>
    <description>combination treatment of 10 mg benazepril and 50 mg losartan per day</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Lotensin+Cozaar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Serum creatinine concentration of 3.0 to 5.0 mg per deciliter (265 to 442 µmol/L)&#xD;
&#xD;
          2. Creatinine clearance of 15 to 30 ml per minute per 1.73m2, with variations of less&#xD;
             than 30 percent in the three months before screening evaluation&#xD;
&#xD;
          3. non-diabetic renal disease&#xD;
&#xD;
          4. Persistent heavier proteinuria (defined by urinary protein excretion of more than 0.3g&#xD;
             per day for three or more months without evidence of urinary tract infection or overt&#xD;
             heart failure [a New York Heart Association class of Ⅲ or Ⅳ])&#xD;
&#xD;
          5. had not received ACE inhibitors or ARBs for at least two weeks before screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No history of allergic reaction to drugs, especially ACE inhibitors and/or ARBs&#xD;
&#xD;
          2. Hyper-or hypokalemia (serum potassium concentration 5.6 mmol per liter or more，or 3.5&#xD;
             mmol per liter or less)&#xD;
&#xD;
          3. Malignant hypertension (blood pressure &gt;180/120 mm Hg) or blood pressure &lt;110mm Hg&#xD;
             without antihypertensive treatment&#xD;
&#xD;
          4. Treatment with drugs affecting serum potassium such as diuretic, β2 receptor blocker&#xD;
             et al.&#xD;
&#xD;
          5. Treatment with corticosteroids, non-steroidal anti-inflammatory drugs, or&#xD;
             immunosuppressive drugs, especially ciclosporin A&#xD;
&#xD;
          6. Myocardial infarction or cerebrovascular accident in the year preceding the trial&#xD;
&#xD;
          7. Nephrotic syndrome (albuminaemia less than 25 g/L)&#xD;
&#xD;
          8. Renovascular disease or connective-tissue disease&#xD;
&#xD;
          9. Obstructive uropathy&#xD;
&#xD;
         10. Immediate need for dialysis&#xD;
&#xD;
         11. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fan Fan Hou, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renal Division, Nanfang Hospital,Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renal Division, Nanfang Hospital,Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <last_update_submitted>April 2, 2016</last_update_submitted>
  <last_update_submitted_qc>April 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal insufficiency</keyword>
  <keyword>Benazepril</keyword>
  <keyword>Losartan</keyword>
  <keyword>combination treatment</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Benazepril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

